Refine by
Healthcare Product Articles & Analysis
154 news found
Many medical devices are manufactured through plastic injection moulding, which allows for precise and top-quality components in large-scale production and better aligns with ISO standards. In general, injection moulding for medical devices is conducted in an ISO 8 clean room environment to ensure all products adhere to the strictest standards of sterility and ...
As a contract research and development biotechnology firm, CD Formulation establishes new benchmarks for health care product development by delivering extensive product formulation services. From initial design to final packaging, the integrated service portfolio helps establish its central position in health care product development. The company provides multiple product types designed to meet ...
With the New Year holiday just around the corner, CD Formulation is delighted to announce a limited-time promotional offer for industries seeking innovative solutions in pharmaceutical, cosmetic, and healthcare product development. From November 15, 2024, to January 5, 2025, clients can benefit from a substantial 5%-15% discount on all products ...
Emphasizing its commitment to supporting educational and research institutions, the promotion offers up to 10% off on all their products and services. This timely initiative aims to facilitate ground-breaking research and innovation in pharmaceutical, cosmetic, and healthcare product formulations. ...
CD Formulation, a leading provider of bioformulation and analytical services, is spreading holiday cheer in 2023 with an exciting offer for its valued customers. The company is extending a generous discount on its range of innovative products and services, allowing customers to make the most of their holiday budget. Being at the forefront of the biotechnology industry, CD Formulation provides ...
In the rapidly evolving landscape of healthcare, there is a growing demand for customized and innovative products to meet the specific needs of customers. CD Formulation, a leading company in the healthcare industry, is at the forefront of this evolution, providing cutting-edge solutions for the customization and development of shaped ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
ByBayer AG
Earlier this month, the management of CD Formulation announced a new decision to expand its one-stop solution for healthcare products. Following this move, clients can count on CD Formulation for the development and OEM/ODM of healthcare products, including formulation development, sensory evaluation, quality assessment, and ...
This move is made because the company plans to further diversify its product lineup, in the hope to offer clients even more options. For many manufacturers either in the health care or pharmaceutical industry, choosing the right packaging can be a critical part of the product development process. ...
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis management that aims to uncouple efficacy from ...
ByBayer AG
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 ...
ByBayer AG
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...
ByBayer AG
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage Bayer further expands ...
ByBayer AG
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the ...
ByBayer AG
As a trust-worthy biochemical company, we are well-prepared to introduce new product lines to meet the needs of both researchers and manufacturers,” said the Marketing Chief of CD Formulation. ...
European Commission granted approval of Nubeqa (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) Approval is based on Phase III ARASENS trial data The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation ...
ByBayer AG
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with ...
ByBayer AG
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate ...
ByBayer AG
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores potential of AI and digital advances in medical imaging Bayer announced today that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The ...
ByBayer AG
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ADT in combination ...
ByBayer AG